Page 4 - Replimune Group News Today

By Dean Seal A clinical trial of Replimune Group's RP1 as a treatment for cutaneous squamous cell carcinoma failed to meet its primary endpoints. The...

Replimune Group said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by...

(Reuters) - Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove ...

Research Analysts’ updated eps estimates for Monday, November 13th: Aadi Bioscience (NASDAQ:AADI) had its price target reduced by HC Wainwright from $45.00 to $36.00. HC Wainwright currently has a buy rating on the stock. Annexon (NASDAQ:ANNX) had its price target trimmed by Needham & Company LLC from $24.00 to $16.00. They currently have a buy […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in […]

Wedbush reissued their outperform rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $52.00 price objective on the stock. Wedbush also issued estimates for Replimune Group’s Q3 2024 earnings at ($0.90) EPS, FY2024 earnings at ($3.57) EPS, FY2025 earnings […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $13.34 and last traded at $13.34, with a volume of 529686 shares traded. The stock had previously closed at $14.29. Analyst Ratings Changes Separately, HC Wainwright reduced their price objective on […]

Oncolytic Adenovirus MarketDuring the forecast period 2023 to 2033, the oncolytic adenovirus market is expected to grow at a value of 7.5% CAGR, according to Future Market Insights. By the year 2033, the global market for oncolytic adenovirus is expected to rise up to a market valuation of US$ 250 Billion. Growth of...

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $15.33 and last traded at $15.41, with a volume of 25155 shares traded. The stock had previously closed at $16.17. Analyst Ratings Changes Separately, HC Wainwright dropped their target […]

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 2,604 put options on the company. This represents an increase of 110% compared to the average volume of 1,239 put options. Replimune Group Stock Performance REPL traded down $0.25 during trading on Wednesday, hitting […]